secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001628280-25-047188
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen appoints Paul Edick to Board of Directors, effective October 27, 2025
------------------------------------------------------------------------------

- Mr. Edick appointed to Board, Audit Committee, and Compensation Committee.
- Received options to purchase 35,200 shares at $3.90/share (closing price on appointment date), vesting over 3 years.
- He is entitled to annual cash and equity compensation under the Director Compensation Plan.
- Mr. Edick is former Chairman/CEO of Xeris Pharmaceuticals and ex-CEO of Durata Therapeutics.
- No family relationships or transactions with the company requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025047188/0001628280-25-047188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025047188/vtgn-20251027.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-047188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer